Two decades of PARP inhibitor synthetic lethality in cancer

Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 , 917–921 (2005). ADS CAS PubMed Google Scholar Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 , 913–917 (2005). Together with Farmer et al. (2005), this study describes the discovery of the BRCA1/2 versus PARPi synthetic lethal effects. ADS CAS PubMed Google Scholar Weinstein, I. B. Cancer. Addiction to oncogenes — the Achilles heal of cancer. Science 297 , 63–64 (2002). CAS PubMed Google Scholar Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278 , 1064–1068 (1997). ADS CAS PubMed Google Scholar Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5 , 689–698 (2005). CAS PubMed Google Scholar Brummelkamp, T. R. & Bernards, R. New tools for functional mammalian cancer genetics. Nat. Rev. Cancer 3 , 781–789 (2003). CAS PubMed Google Scholar McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66 , 8109–8115 (2006). CAS PubMed Google Scholar Schultz, N., Lopez, E., Saleh-Gohari, N. & Helleday, T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 31 , 4959–4964 (2003). …